Middle East & Africa Biosimilars Market Size & Outlook
Middle East & Africa biosimilars market, 2016-2027 (US$M)
Related Markets
MEA biosimilars market highlights
- The MEA biosimilars market generated a revenue of USD 746.2 million in 2020.
- The market is expected to grow at a CAGR of 13.7% from 2021 to 2027.
- In terms of segment, recombinant non-glycosylated proteins was the largest revenue generating product in 2020.
- Recombinant Glycosylated Proteins is the most lucrative product segment registering the fastest growth during the forecast period.
- Country-wise, South Africa is expected to register the highest CAGR from 2021 to 2027.
MEA data book summary
| Market revenue in 2020 | USD 746.2 million |
| Market revenue in 2027 | USD 1,834.0 million |
| Growth rate | 13.7% (CAGR from 2020 to 2027) |
| Largest segment | Recombinant non-glycosylated proteins |
| Fastest growing segment | Recombinant Glycosylated Proteins |
| Historical data covered | 2016 - 2019 |
| Base year for estimation | 2020 |
| Forecast period covered | 2021 - 2027 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Recombinant Non-Glycosylated Proteins, Recombinant Glycosylated Proteins |
| Key market players worldwide | Amgen Inc, Roche, Sandoz Group AG ADR, Dr. Reddy’s Laboratories, Teva Pharmaceutical Industries Ltd, Pfizer Inc, Samsung Bioepis, Biocon, Viatris Inc, Celltrion Healthcare, AbbVie Inc |
Other key industry trends
- In terms of revenue, MEA region accounted for 5.6% of the global biosimilars market in 2020.
- Globally, North America is projected to lead the regional market in terms of revenue in 2027.
- North America is the fastest growing regional market and is projected to reach USD 17,204.5 million by 2027.
Key Regions: U.S. , UK , Japan , Brazil , South Africa
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Biosimilars Market Scope
Biosimilars Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Middle East & Africa biosimilars market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biosimilars market will help companies and investors design strategic landscapes.
Recombinant non-glycosylated proteins was the largest segment with a revenue share of 54.32% in 2020. Horizon Databook has segmented the Middle East & Africa biosimilars market based on recombinant non-glycosylated proteins, recombinant glycosylated proteins covering the revenue growth of each sub-segment from 2016 to 2027.
Launch of new biosimilars in the region is one of the key factors anticipated to fuel market growth in the near future. For instance, in September 2019, Celltrion, Inc. launched a gastric and breast cancer biosimilar, Herzuma, in Iraq.
The company is preparing for the launch of biosimilars in other gulf countries, such as Israel, Jordan, Saudi Arabia, UAE, and Morocco. The biosimilar has gained about 80% market share in Morocco and is also distributed to various public health institutions in Jordan and Saudi Arabia.
In some low- and middle-income MEA countries, the medium availability of biosimilars can be attributed to various factors, such as absence of an assertive & proactive approach to establish infrastructure for biologic products, lack of awareness about various treatment pathways leading to low biosimilar uptake, and a robust regulatory framework that assures the approval of safe & efficacious biosimilars.
Reasons to subscribe to Middle East & Africa biosimilars market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Middle East & Africa biosimilars market databook
-
Our clientele includes a mix of biosimilars market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Middle East & Africa biosimilars market , including forecasts for subscribers. This continent databook contains high-level insights into Middle East & Africa biosimilars market from 2016 to 2027, including revenue numbers, major trends, and company profiles.
Partial client list
MEA biosimilars market size, by country, 2016-2027 (US$M)
Middle East & Africa Biosimilars Market Outlook Share, 2020 & 2027 (US$M)
Related industry reports
Related regional statistics
No records
No related regions found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
